Skip to main content

Market Overview

Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows

Share:
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
  • Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF)
  • The data were presented at the American Society for Cell and Gene Therapy (ASGCT) meeting.
  • Data Highlights:
    • HiTs are CD8 and HLA-independent and kill mesothelin expressing human tumor cells.
    • Data demonstrate that the mesothelin HiT is not dependent on CD8 to kill target cells, and CD4 cells expressing the HiT are cytotoxic towards tumor cells.
    • Data from additional in vitro experiments show that Adaptimmune's HiT is not neutralized by soluble mesothelin, unlike the TRuC construct.
    • HiT T-cells targeting mesothelin induced complete tumor regression in a mouse xenograft tumor model and outperformed a comparator TRuC construct.
  • Price Action: ADAP shares are up 2.1% at $4.82 during the market trading session on the last check Tuesday.
 

Related Articles (ALPMY + ALPMF)

View Comments and Join the Discussion!

Posted-In: Briefs cancerBiotech News Penny Stocks Health Care Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com